The prescription-only peanut allergy treatment Palforzia® will be discontinued on 31 July 2026, according to its manufacturer, Stallergenes Greer. The therapy received approval from the U.S. Food and Drug Administration (FDA) in 2020.
Palforzia is the only oral immunotherapy approved by the FDA for the treatment of peanut allergy in children aged 1 to 17. Because of the risk of severe allergic reactions, it is available only through a restricted access program known as the Palforzia Risk Evaluation and Mitigation Strategy (REMS). The treatment is not used to manage acute allergic reactions, including anaphylaxis, and patients must maintain a strict peanut-free diet while taking it.
Stallergenes Greer has stated that the voluntary discontinuation is not related to product safety, quality or efficacy, and says it will support an orderly transition for healthcare professionals and patients currently receiving the therapy.
Palforzia was originally developed by Aimmune Therapeutics. Nestlé Health Science later acquired Aimmune before selling the product to Stallergenes Greer, a private biopharmaceutical company specialising in allergy immunotherapy.
See the Stallergenes Greer website for more information.
